Results 181 to 190 of about 59,165 (246)

The Challenge of Time-to-Event Analysis for Multiple Events: A Guided Tour From Time-to-First-Event to Recurrent Time-to-Event Analysis. [PDF]

Biom J
Schmeller S, Erdmann A, Beyersmann J, Angermann C, Ozga AK.   +4 more
europepmc   +1 more source

NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial

The Laryngoscope, EarlyView.
This 2‐year, single‐center, double‐blind study with a small sample size compared NAD+ and control groups in a randomized controlled trial for sudden sensorineural hearing loss (SSNHL). Results showed that NAD+ led to better hearing improvement from 7 days to 3 months and a shorter average recovery time compared to the control group.
Minqian Gao, Yingting Guan, Xuejing Yue, Hao Bao, Qianwen Li, Yiqing Zheng, Yongkang Ou, Haidi Yang   +7 more
wiley   +1 more source

High-flow nasal cannula and intubation risk in severe PjP: methodological and clinical perspectives. [PDF]

Ann Intensive Care
Wang L, Cheng J.
europepmc   +1 more source

Discrete-time neural Markov models. [PDF]

BMC Med Res Methodol
Sundell J, Wahlquist Y, Soltesz K.
europepmc   +1 more source

A Genome‐Wide Association Study of Colorectal Cancer Mortality Outcomes Among Individuals of African and Admixture Ancestry

Molecular Carcinogenesis, EarlyView.
ABSTRACT African Americans have the highest colorectal cancer (CRC) mortality rates in the United States. We performed the first genome‐wide association study (GWAS) of overall and CRC‐specific mortality among African Americans with incident CRC to identify genetic contributors to CRC outcomes.
Thomas Lawler, Jirong Long, Rene Welch, Irene Ong, Oluwatoyosi Ogunmuyiwa, Rida A. Khatri, Martha Shrubsole, Shaneda Warren Andersen   +7 more
wiley   +1 more source

Estimating quantile treatment effect on the original scale of the outcome variable: a case study of common cold treatments. [PDF]

Trials
Hemilä H, Pirinen M.
europepmc   +1 more source

Comparative Analysis of the Incidence, Prevalence, and Survival of 8 Types of Parkinsonism in a Population‐Based Study with 367 Million Person Years of Observation over 21 Years

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Findings are contradictory regarding changes in the incidence and prevalence of Parkinson's disease (PD) over time; data for other parkinsonian disorders are rare. Objectives To analyze temporal trends in the incidence and prevalence of eight parkinsonisms (PD, MSA, PSP, CBS, DLB, vascular parkinsonism, drug‐induced parkinsonism ...
Sacha E. Gandhi, Katherine A. Grosset, Prasanth A. Iruthayaraj, Romel Gravesande, Lance Lee, Cathal Doyle, Yoav Ben‐Shlomo, Donald G. Grosset   +7 more
wiley   +1 more source

Handling missing outcomes in time-to-event analyses in randomised controlled trials: a scoping review with a focus on multiple imputation. [PDF]

BMC Med Res Methodol
Karuppasamy S, Premkumar PS, Mohan VR.
europepmc   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge, Jeffrey Rothstein, Shari De Silva, Lorne Zinman, Marvin Chum, Adriano Chiò, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic, Manabu Hirai, Nissim Sasson, Fumihiro Takahashi, Michelle Cecić, Art Wamil, Stephen Apple   +17 more
wiley   +1 more source

Model-Free Approach to Evaluate a Censored Intermediate Outcome as a Surrogate for Overall Survival. [PDF]

Stat Med
Wang X, Cai T, Tian L, Parast L.
europepmc   +1 more source